Altimmune (MEX:ALT1) Short-term investments

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

MEX:ALT1 Altimmune Inc MEX:ALT1
41 GF Score
Price MXN52.50
GF Value MXN5.37
Valuation Significantly Overvalued
! 2 Warning Signs
View Full Analysis

What is Altimmune Short-term investments?

Short-term investments only applies to insurance companies.

MEX:ALT1
41GF Score
Altimmune Inc MEX:ALT1
Short-term investments is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Altimmune (MEX:ALT1) Overvalued in 2026?

Based on GuruFocus' analysis, Altimmune stock appears to be overvalued. The current stock price of MXN52.50 is trading 877.7% above its estimated GF Value™ of MXN5.37. GuruFocus considers Altimmune to be Significantly Overvalued.

Key valuation signals for MEX:ALT1:

  • Short-term investments:
  • GF Value™: MXN5.37 vs. price of MXN52.50 (877.7% above fair value)
  • GF Score™: 41/100 with 2 warning signs

No single metric tells the full story. See the MEX:ALT1 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Altimmune Business Description

Other Exchanges ALT:USA0A4C:UK3G0:Germany
Address 910 Clopper Road, Suite 201S, Gaithersburg, MD, USA, 20878
Altimmune Inc is a late clinical-stage biopharmaceutical company developing therapies for patients with serious liver diseases. The Company's key candidate, pemvidutide, is a dual-action therapy targeting both glucagon and GLP-1 receptors in a balanced 1:1 ratio in development for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), alcohol use disorder (AUD), and alcohol-associated liver disease (ALD). The company also plans to pursue additional indications for pemvidutide that leverage the differentiated clinical profile of pemvidutide.
41GF Score

Get the complete analysis for MEX:ALT1

Short-term investments is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

MXN52.50
Price
MXN5.37
GF Value